{"success":true,"data":{"pressRelease":{"id":"71661","rtpr_id":"nWkr8Rsb67","ticker":"HLUNA","exchange":"Nasdaq Copenhagen","all_tickers":["HLUNA"],"title":"Tarek Samad appointed EVP, Head of Research & Development at Lundbeck","author":"Cision","published_at":"2026-06-24T09:30:13.441Z","article_body":"H. Lundbeck A/S\nValby, Denmark, 24 June, 2026 – H. Lundbeck A/S (Lundbeck) today announced\nthat Tarek Samad has been appointed Executive Vice President and Head of\nResearch & Development (R&D) and will join the Executive Leadership Team (ELT)\neffective 1 September 2026.\n\nTarek Samad succeeds Johan Luthman, who has informed the Board of Directors\nand ELT of his decision to retire after seven years with Lundbeck.\n\nA transition period will commence in July 2026 to ensure a seamless handover\nof responsibilities, and Johan Luthman will remain with Lundbeck until the end\nof 2026 to ensure continuity across key strategic and scientific priorities.\n\n“I would like to thank Johan Luthman for his outstanding contributions to\nLundbeck. Under his leadership, our R&D organization has undergone a major\nrestructuring and shift in scientific focus and capabilities. Johan has played\na key role in establishing a transformed, innovative pipeline while bringing\nimportant new products to the market in line with our Focused Innovator\nstrategy,” said CEO Charl van Zyl. “At the same time, I am pleased to\nwelcome Tarek Samad to the ELT. Through his leadership of our Research\norganization, I have seen firsthand his ability to advance scientific\nexcellence, build high-performing teams, and leverage strategic partnerships\nand emerging technologies to strengthen our innovation engine. Tarek has been\na key contributor to the development and execution of our R&D strategy and to\nthe progress we have achieved across our pipeline. As we continue to build on\nthe momentum, I am confident that Tarek Samad is the right leader to guide our\nR&D organization through its next phase of innovation and growth, delivering\nmeaningful advances for patients.”\n\nTarek Samad currently serves as Senior Vice President, Global Head of Research\nand Corporate Patents at Lundbeck, where he has led the company's global\nresearch organization since 2021 and played an instrumental role in executing\nLundbeck’s R&D strategy, advancing its innovation capabilities and\nstrengthening its research collaborations. His appointment reflects Lundbeck's\nstrong internal talent pipeline and commitment to leadership continuity. Prior\nto joining Lundbeck, Tarek Samad held senior research leadership positions at\nImmunitas Therapeutics, Sanofi and Pfizer, and previously served on the\nfaculty of Harvard Medical School and Massachusetts General Hospital.\n\n“I am excited to take on the role of EVP and Head of Research & Development\nand to join Lundbeck's Executive Leadership Team,” said Tarek Samad.\n“Lundbeck combines a unique legacy of scientific excellence with an\nunwavering commitment to advancing innovation and improving the lives of\npeople living with brain diseases. Over the past five years, I have had the\nprivilege of working alongside Johan and the broader R&D organization to\nadvance our science, strengthen our capabilities, and accelerate the progress\nof our pipeline. I look forward to building on this strong foundation and\nworking with colleagues across Lundbeck and our external partners to deliver\ntransformative treatments for patients.”\n\nTarek Samad succeeds Johan Luthman, who has led Lundbeck's R&D organization\nsince 2019. Under his leadership, Lundbeck’s scientific competence and\nexpertise have been substantially transformed. While establishing broader drug\nmodality platforms and transitioning into new biological research areas, the\ncompany has built a richer, innovative pipeline, dominated by first-in-class\nopportunities across development stages. During Johan’s tenure, R&D has\ndelivered successful new products and lifecycle management across global\nmarkets, reinforcing Lundbeck’s leadership in neuroscience.\n\n“After seven exciting years at Lundbeck, I believe this is the right time to\ntransition the leadership of the R&D organization,” said Johan Luthman.\n“Through dedicated efforts and passion for science and patients, we have\nfundamentally changed the trajectory of Lundbeck. Our major transformation\nover several years has significantly expanded our innovation potential and\npositioned us to be truly premier in neuroscience R&D. We have brought\ninnovative new medicines to patients, provided strong support for our\nproducts, and built a promising future for Lundbeck. I am proud of what we\nhave achieved and immensely grateful to all the talented colleagues who have\nmade this progress possible, and I am delighted to see Tarek Samad appointed\nas my successor.”\nContacts\n Jens Høyer                                  Anders Crillesen                                \n Vice President, Head of Investor Relations  Senior Director, External & Internal Relations  \n JSHR@lundbeck.com                           AECE@lundbeck.com                               \n +45 30 83 45 01                             +45 29 79 12 86                                 \n                                                                                             \nAbout H. Lundbeck A/S\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect\nwith us via LinkedIn\n(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flundbeck%2F&data=05%7C02%7CMJKJ%40lundbeck.com%7C7e687e1221b94185debd08de3277246a%7Cca625151ac0044419024c88fad6084da%7C0%7C0%7C639003684489901459%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bX5GpFb8H21rowTneq%2F9LeTO3NOBPtbwAlN56ldlUwk%3D&reserved=0).\n\nSafe Harbor/Forward-Looking Statements\n\nThis corporate release contains forward-looking statements that provide our\nexpectations or forecasts of future events such as new product introductions,\nproduct approvals and financial performance. Forward looking statements\ninclude, without limitation, any statement that may predict, forecast,\nindicate or imply future results, performance or achievements, and may contain\nwords like \"believe\", \"anticipate\", \"expect\", \"estimate\", \"intend\", \"plan\",\n\"project\", \"will be\", \"will continue\", \"will result\", \"could\", \"may\", \"might\",\nor any variations of such words or other words with similar meanings. All\nstatements other than statements of historical facts included in this\ncorporate release, including, without limitation, those regarding our\nfinancial position, business strategy, plans and objectives of management for\nfuture operations (including development plans and objectives relating to our\nproducts), are forward looking statements.\n\nSuch forward looking statements involve known and unknown risks, uncertainties\nand other factors which may cause our actual results, performance or\nachievements to be materially different from any future results, performance\nor achievements expressed or implied by such forward looking statements.\nFactors that may affect future results include, among others, interest rate\nand currency exchange rate fluctuations, delay or failure of development\nprojects, production or distribution problems, unexpected contract breaches or\nterminations, government-mandated or market-driven price decreases for\nLundbeck's products, introduction of competing products, Lundbeck's ability to\nsuccessfully market both new and existing products, exposure to product\nliability and other lawsuits, changes in reimbursement rules and governmental\nlaws and related interpretation thereof, and unexpected growth in costs and\nexpenses.\n\nThe forward-looking statements in this document and in oral presentations made\non behalf of Lundbeck speak only as at the date of this document. Lundbeck\ndoes not undertake any obligation to update or revise forward-looking\nstatements in this corporate release or oral presentations made on behalf of\nLundbeck, nor to confirm such statements to reflect subsequent events or\ncircumstances after the date of the release, presentation or in relation to\nactual results, unless otherwise required by applicable law or applicable\nstock exchange regulations.\n\n \n\nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/tarek-samad-appointed-evp--head-of-research---development-at-lundbeck%2Cc4366975\n\nCompany Announcement_Final\n(https://mb.cision.com/Main/18215/4366975/4165156.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr8Rsb67","title":"Tarek Samad appointed EVP, Head of Research & Development at Lundbeck","author":"Cision","ticker":"HLUNA","created":"2026-06-24T09:30:13.441Z","tickers":["HLUNA"],"exchange":"Nasdaq Copenhagen","article_body":"H. Lundbeck A/S\nValby, Denmark, 24 June, 2026 – H. Lundbeck A/S (Lundbeck) today announced\nthat Tarek Samad has been appointed Executive Vice President and Head of\nResearch & Development (R&D) and will join the Executive Leadership Team (ELT)\neffective 1 September 2026.\n\nTarek Samad succeeds Johan Luthman, who has informed the Board of Directors\nand ELT of his decision to retire after seven years with Lundbeck.\n\nA transition period will commence in July 2026 to ensure a seamless handover\nof responsibilities, and Johan Luthman will remain with Lundbeck until the end\nof 2026 to ensure continuity across key strategic and scientific priorities.\n\n“I would like to thank Johan Luthman for his outstanding contributions to\nLundbeck. Under his leadership, our R&D organization has undergone a major\nrestructuring and shift in scientific focus and capabilities. Johan has played\na key role in establishing a transformed, innovative pipeline while bringing\nimportant new products to the market in line with our Focused Innovator\nstrategy,” said CEO Charl van Zyl. “At the same time, I am pleased to\nwelcome Tarek Samad to the ELT. Through his leadership of our Research\norganization, I have seen firsthand his ability to advance scientific\nexcellence, build high-performing teams, and leverage strategic partnerships\nand emerging technologies to strengthen our innovation engine. Tarek has been\na key contributor to the development and execution of our R&D strategy and to\nthe progress we have achieved across our pipeline. As we continue to build on\nthe momentum, I am confident that Tarek Samad is the right leader to guide our\nR&D organization through its next phase of innovation and growth, delivering\nmeaningful advances for patients.”\n\nTarek Samad currently serves as Senior Vice President, Global Head of Research\nand Corporate Patents at Lundbeck, where he has led the company's global\nresearch organization since 2021 and played an instrumental role in executing\nLundbeck’s R&D strategy, advancing its innovation capabilities and\nstrengthening its research collaborations. His appointment reflects Lundbeck's\nstrong internal talent pipeline and commitment to leadership continuity. Prior\nto joining Lundbeck, Tarek Samad held senior research leadership positions at\nImmunitas Therapeutics, Sanofi and Pfizer, and previously served on the\nfaculty of Harvard Medical School and Massachusetts General Hospital.\n\n“I am excited to take on the role of EVP and Head of Research & Development\nand to join Lundbeck's Executive Leadership Team,” said Tarek Samad.\n“Lundbeck combines a unique legacy of scientific excellence with an\nunwavering commitment to advancing innovation and improving the lives of\npeople living with brain diseases. Over the past five years, I have had the\nprivilege of working alongside Johan and the broader R&D organization to\nadvance our science, strengthen our capabilities, and accelerate the progress\nof our pipeline. I look forward to building on this strong foundation and\nworking with colleagues across Lundbeck and our external partners to deliver\ntransformative treatments for patients.”\n\nTarek Samad succeeds Johan Luthman, who has led Lundbeck's R&D organization\nsince 2019. Under his leadership, Lundbeck’s scientific competence and\nexpertise have been substantially transformed. While establishing broader drug\nmodality platforms and transitioning into new biological research areas, the\ncompany has built a richer, innovative pipeline, dominated by first-in-class\nopportunities across development stages. During Johan’s tenure, R&D has\ndelivered successful new products and lifecycle management across global\nmarkets, reinforcing Lundbeck’s leadership in neuroscience.\n\n“After seven exciting years at Lundbeck, I believe this is the right time to\ntransition the leadership of the R&D organization,” said Johan Luthman.\n“Through dedicated efforts and passion for science and patients, we have\nfundamentally changed the trajectory of Lundbeck. Our major transformation\nover several years has significantly expanded our innovation potential and\npositioned us to be truly premier in neuroscience R&D. We have brought\ninnovative new medicines to patients, provided strong support for our\nproducts, and built a promising future for Lundbeck. I am proud of what we\nhave achieved and immensely grateful to all the talented colleagues who have\nmade this progress possible, and I am delighted to see Tarek Samad appointed\nas my successor.”\nContacts\n Jens Høyer                                  Anders Crillesen                                \n Vice President, Head of Investor Relations  Senior Director, External & Internal Relations  \n JSHR@lundbeck.com                           AECE@lundbeck.com                               \n +45 30 83 45 01                             +45 29 79 12 86                                 \n                                                                                             \nAbout H. Lundbeck A/S\nLundbeck is a biopharmaceutical company focusing exclusively on brain health.\nWith more than 70 years of experience in neuroscience, we are committed to\nimproving the lives of people with neurological and psychiatric diseases.\n\nBrain disorders affect a large part of the world’s population, and the\neffects are felt throughout society. With the rapidly improving understanding\nof the biology of the brain, we hold ourselves accountable for advancing brain\nhealth by curiously exploring new opportunities for treatments.\n\nAs a focused innovator, we strive for our research and development programs to\ntackle some of the most complex neurological challenges. We develop\ntransformative medicines targeting people for whom there are few or no\ntreatments available, expanding into neuro-specialty and neuro-rare from our\nstrong legacy within psychiatry and neurology.\n\nWe are committed to fighting stigma and we act to improve health equity. We\nstrive to create long term value for our shareholders by making a positive\ncontribution to patients, their families and society as a whole.\n\nLundbeck has more than 5,000 employees in more than 20 countries and our\nproducts are available in more than 80 countries. For additional information,\nwe encourage you to visit our corporate site www.lundbeck.com and connect\nwith us via LinkedIn\n(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flundbeck%2F&data=05%7C02%7CMJKJ%40lundbeck.com%7C7e687e1221b94185debd08de3277246a%7Cca625151ac0044419024c88fad6084da%7C0%7C0%7C639003684489901459%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bX5GpFb8H21rowTneq%2F9LeTO3NOBPtbwAlN56ldlUwk%3D&reserved=0).\n\nSafe Harbor/Forward-Looking Statements\n\nThis corporate release contains forward-looking statements that provide our\nexpectations or forecasts of future events such as new product introductions,\nproduct approvals and financial performance. Forward looking statements\ninclude, without limitation, any statement that may predict, forecast,\nindicate or imply future results, performance or achievements, and may contain\nwords like \"believe\", \"anticipate\", \"expect\", \"estimate\", \"intend\", \"plan\",\n\"project\", \"will be\", \"will continue\", \"will result\", \"could\", \"may\", \"might\",\nor any variations of such words or other words with similar meanings. All\nstatements other than statements of historical facts included in this\ncorporate release, including, without limitation, those regarding our\nfinancial position, business strategy, plans and objectives of management for\nfuture operations (including development plans and objectives relating to our\nproducts), are forward looking statements.\n\nSuch forward looking statements involve known and unknown risks, uncertainties\nand other factors which may cause our actual results, performance or\nachievements to be materially different from any future results, performance\nor achievements expressed or implied by such forward looking statements.\nFactors that may affect future results include, among others, interest rate\nand currency exchange rate fluctuations, delay or failure of development\nprojects, production or distribution problems, unexpected contract breaches or\nterminations, government-mandated or market-driven price decreases for\nLundbeck's products, introduction of competing products, Lundbeck's ability to\nsuccessfully market both new and existing products, exposure to product\nliability and other lawsuits, changes in reimbursement rules and governmental\nlaws and related interpretation thereof, and unexpected growth in costs and\nexpenses.\n\nThe forward-looking statements in this document and in oral presentations made\non behalf of Lundbeck speak only as at the date of this document. Lundbeck\ndoes not undertake any obligation to update or revise forward-looking\nstatements in this corporate release or oral presentations made on behalf of\nLundbeck, nor to confirm such statements to reflect subsequent events or\ncircumstances after the date of the release, presentation or in relation to\nactual results, unless otherwise required by applicable law or applicable\nstock exchange regulations.\n\n \n\nH. Lundbeck A/S\n\nOttiliavej 9, 2500 Valby, Denmark\n\n+45 3630 1311\n\ninfo@lundbeck.com\n\nhttps://news.cision.com/h--lundbeck-a-s/r/tarek-samad-appointed-evp--head-of-research---development-at-lundbeck%2Cc4366975\n\nCompany Announcement_Final\n(https://mb.cision.com/Main/18215/4366975/4165156.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-06-24T09:30:13.597931153Z","server_sent_at_ms":1782293413597},"received_at":"2026-06-24T09:30:13.665Z","source_url":"https://news.cision.com/h--lundbeck-a-s/r/tarek-samad-appointed-evp--head-of-research---development-at-lundbeck%2Cc4366975"},"analysis":{"id":"61037","press_release_id":"71661","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Tarek Samad has been appointed Executive Vice President and Head of Research & Development at Lundbeck, effective September 1, 2026.\n\nHe succeeds Johan Luthman, who is retiring after seven years with the company; Luthman will remain until the end of 2026 to ensure a seamless handover of responsibilities.\n\nSamad is currently the SVP, Global Head of Research, and his appointment reflects an internal succession plan designed to maintain leadership continuity within the R&D organization.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Internal promotion ensures R&D continuity as Lundbeck's longtime head of research retires."},"keyFigures":null,"quotedText":"I would like to thank Johan Luthman for his outstanding contributions to Lundbeck.","namedEntities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development (Appointed)"},{"name":"Johan Luthman","role":"Executive Vice President and Head of Research & Development (Retiring)"},{"name":"Charl van Zyl","role":"CEO"}],"products":[],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA"},{"name":"Immunitas Therapeutics","relationship":"former employer"},{"name":"Sanofi","relationship":"former employer"},{"name":"Pfizer","relationship":"former employer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Planned succession of the EVP, Head of R&D via internal promotion ensures strategic continuity; not a CEO departure or unexpected disruption."},"tickerRelevance":{"others":[],"primary":"HLUNA"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-foreign","eventGravity":"executive-succession"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Tarek Samad has been appointed Executive Vice President and Head of Research & Development at Lundbeck, effective September 1, 2026.\n\nHe succeeds Johan Luthman, who is retiring after seven years with the company; Luthman will remain until the end of 2026 to ensure a seamless handover of responsibilities.\n\nSamad is currently the SVP, Global Head of Research, and his appointment reflects an internal succession plan designed to maintain leadership continuity within the R&D organization.","key_figures":null,"named_entities":{"people":[{"name":"Tarek Samad","role":"Executive Vice President and Head of Research & Development (Appointed)"},{"name":"Johan Luthman","role":"Executive Vice President and Head of Research & Development (Retiring)"},{"name":"Charl van Zyl","role":"CEO"}],"products":[],"companies":[{"name":"H. Lundbeck A/S","ticker":"HLUNA"},{"name":"Immunitas Therapeutics","relationship":"former employer"},{"name":"Sanofi","relationship":"former employer"},{"name":"Pfizer","relationship":"former employer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-24T09:33:34.010Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap-foreign","eventGravity":"executive-succession"}},"durationMs":161616,"modelName":"george-droid-qwen-72b"}}